Pioda Tablet 10/15 mg (Dapagliflozin, Pioglitazone)

Adult dosage

The recommended dosage for patients receiving dapagliflozin 10 mg and pioglitazone 15 mg is one tablet daily, regardless of meals. The tablet should not be divided. For patients who cannot achieve adequate blood sugar control with metformin and dapagliflozin, the recommended dosage is one tablet of dapagliflozin 10 mg/pioglitazone 15 mg once daily.

This medication should not be administered to patients with heart failure or a history of heart failure. One of the components of this medication, pioglitazone, can exacerbate or cause new heart failure, so after administration, signs of heart failure such as rapid weight gain, difficulty breathing, and swelling should be closely monitored. If any of these symptoms occur, notify a healthcare professional immediately, and the administration of this medication should be discontinued or the dosage adjusted as needed. Additionally, this medication should not be used in patients with active bladder cancer or a history of bladder cancer, severe liver dysfunction or kidney dysfunction, type 1 diabetes, or diabetic ketoacidosis. Elderly patients, premenopausal women, patients with edema, and those with heart disease should be particularly cautious when administering this medication. Patients at risk for reduced fluid volume or hypotension should assess their fluid status and kidney function before administration, and blood pressure and kidney function should be continuously monitored after administration. This medication helps with blood sugar control, but hypoglycemic symptoms may occur, so patients at risk for hypoglycemia should be alert to symptoms. Side effects such as weight gain, edema, headaches, urinary tract infections, and genital infections may occur, so if abnormal symptoms present, consult a healthcare professional. If symptoms of liver abnormality (fatigue, decreased appetite, jaundice, etc.) appear, notify a healthcare professional immediately and undergo testing; if liver enzyme levels rise significantly, administration should be stopped. Pregnant women or those who may become pregnant should not use this medication, and it is also not suitable for patients before or after surgery or those with severe infections. During the course of treatment with this medication, regular check-ups and adherence to healthcare professional instructions must be ensured for safe use.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe rash with high fever, blisters, skin peeling, pain in mucous membranes of the mouth/eyes, shortness of breath or difficulty breathing, asthma attacks, respiratory difficulties accompanied by cough and fever, yellowing of skin or eyes (jaundice), extreme lethargy, sudden and severe headaches, thunderclap headache, seizures, confusion, vision disturbances, paralysis, urine

Mild side effects

• Headache
• dizziness
• abdominal discomfort
• abdominal pain
• diarrhea
• indigestion
• visual disturbances
• cystitis
• increased blood creatine phosphokinase
• urinary retention

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is advisable to keep it at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness and safety.

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle